Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon in chronic myeloid leukemia. A workshop report

M Griesshammer1, R Hehlmann, A Hochhaus

  • 1III. Medizinische Klinik, Universität Ulm, Germany.

Annals of Hematology
|August 1, 1993
PubMed
Summary

Interferon-alpha shows promise in treating chronic myeloid leukemia, potentially eradicating cancer cells in some patients. However, its overall survival benefit compared to traditional drugs remains unproven, with ongoing debate on optimal treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic and therapeutic challenges in claudin 18.2-positive gastric cancer treated with zolbetuximab: Intrapatient heterogeneity or secondary loss of expression?

Journal of cancer research and clinical oncology·2026
Same author

Things that drive Editors crazy: jargon, unnecessary abbreviations, abusing decimals and a few more.

Leukemia·2025
Same author

Mpox in people with haematological cancers.

Leukemia·2024
Same author

The JAK1/2 inhibitor ruxolitinib in patients with COVID-19 triggered hyperinflammation: the RuxCoFlam trial.

Leukemia·2023
Same author

The German Network for Personalized Medicine to enhance patient care and translational research.

Nature medicine·2023
Same author

The impact of specific cytokine directed treatment on severe COVID-19.

Leukemia·2021

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Interferon-alpha (IFN-alpha) is under investigation for chronic myeloid leukemia (CML) treatment.
  • Clinical trials are evaluating its therapeutic efficacy in various settings.

Framework:

  • IFN-alpha can induce responses in many CML patients.
  • Complete eradication of clonogenic cells is achievable in a subset of patients.

Implementation:

  • Optimal dosage, treatment duration, and combination therapies are subjects of ongoing debate.
  • The relevance of cytogenetic and molecular data in assessing response requires further clarification.

Implications:

  • The definitive impact of IFN-alpha on overall survival versus conventional therapies is yet to be established.

Related Experiment Videos

  • An international workshop aimed to clarify the current role of interferon in CML management.